Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/6125

Title: Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study
Authors: van der Burg, M.E.L.
Bolis, G.
Bakker, P.J.M.
CURRAN, Desmond
Sahmoud, T.
Vermorken, J.B.
Issue Date: 1997
Publisher: Elsevier Science Ltd.
Citation: European journal of cancer, 33(9). p. 1513-1515
Abstract: In this study 22 patients with metastatic adenocarcinoma of the cervix were treated with a weekly bolus injection of 4′-epidoxorubicin at a dose of 12 mg/m2. Seventeen patients had received prior radiotherapy, all patients were chemo-naive. Toxicity was generally absent or very mild. One patient had a complete response and 2 patients had a partial response, one was an unconfirmed partial response, giving a response rate of 14%. Six patients had stable disease. The median progression-free survival and overall survival was 2.8 months and 6.1 months, respectively. In conclusion, 4 -epidoxorubicin used at this dosage and schedule has minimal activity in metastatic adenocarcinoma of the cervix.
URI: http://hdl.handle.net/1942/6125
DOI: 10.1016/S0959-8049(97)00172-X
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.